Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Shares of Eli Lilly fell sharply Thursday morning after the pharmaceutical giant's lowered profit projections outweighed ...

Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 trillion stock and the first healthcare ... is justified by its 2025 earnings ...

Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter ...

While maintaining its revenue forecast ... Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t ...

Eli Lilly stock (NYSE: LLY) stock is showing positive ... Inc. Trefis is an interactive financial community structured around trends, forecasts and insights related to some of the most popular ...

Looking at its longer-term performance, Eli Lilly's stock appreciated by 422.93% over the past five ... considering the ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street.

The stock carries a hefty premium, but it is justified by the company's growth and the size of the market for GLP-1s. Eli Lilly's Q1 report ... maintaining its revenue forecast of $58 billion ...

Eli Lilly's Q1 numbers showed strong revenue and earnings growth, driven by its GLP-1 offerings. The company's 2025 outlook disappointed investors, however, leading to the decline. The stock ...